Spanish Heart Transplant Registry. 31th Official Report of the Heart Failure Association of the Spanish Society of Cardiology

González‐Vílchez, Francisco; Almenar‐Bonet, Luis; Crespo‐Leiro, María G.; Gómez‐Bueno, Manuel; González‐Costello, José; Pérez‐Villa, Félix; Delgado-Jiménez, Juan; Prado, José María Arizón del; Sobrino-Márquez, José Manuel; Valero‐Masa, María Jesús

doi:10.1016/j.rec.2020.06.035

Cited by 6 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our mean postoperative stays in ICU and hospital were higher than reported in the USA, Brazil, and Chile (8,14,28). Consistent with most reports, infection was the first cause of death after HTx; however, the second cause was acute rejection, unlike other series, which was primary graft failure (2,13,15). Our overall survival rate was slightly higher than that described by the ISHLT at one, five, and ten years after HTx, and the analysis by age group was also higher, especially in children, as they still have a 100% survival (3).…”

Section: Discussionsupporting

confidence: 89%

“…Regarding pretransplant clinical status, 85.5% had an INTERMACS Profile 1 to 3, similar to ISHLT reports (24). It is a progressive increase of urgent HTx from 36.2% to 46.8% in the last decade in Spain; in our program, the average was 54.2% due to longer waiting times (15). On the contrary, 54.2% of recipients required inotropic support pretransplant, lower than ISHLT's (24).…”

Section: Discussionsupporting

confidence: 78%

“…In addition, the low percentage of pediatric HTx is related to the lower rate of pediatric donors, and it is reflected in the significant difference regarding the waiting time, in which adults' average was 8.9 weeks, and children's, 40.9 weeks. This phenomenon is widely reported (15,16,18). In our experience, most of them have been children due to the lack of donors and the slowly growing number of HTx in developing countries, coinciding with regional experiences (17,20).…”

Section: Discussionsupporting

confidence: 62%

“…Consequently, the ISHLT reports a gradual increase in VADs as bridge-to-transplant in 23% by 2005 and 50.3% by 2019 (24). Likewise, Gonzales et al describe an inverse relationship in the use of IABPs and VADs (15). Our program utilized mechanical support in 14.5% of patients: 6% with IABP and 9.6% with VADs.…”

Section: Discussionmentioning

confidence: 80%

“…Through scientific development, ongoing training, and spreading program formation, HTx is now, to a greater extent, a better opportunity for the treatment of EHF patients around the world (5,(13)(14)(15)(16). However, only 102 countries report their numbers annually to the International Registry in Organ Donation and Transplantation (IRODaT) database (5).…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Heart transplantation at the Peruvian National Heart Institute: One-decade single-center experience

Pinto‐Salinas

Morón-Castro

Chavarri‐Velarde

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Heart transplantations are ideal for most patients with end-stage heart failure refractory to medical treatment. The transplantation program at the Peruvian National Heart Institute started with a 10-year-continuity in 2010. Objective: To report the results of a 10-year heart transplantation experience at the Peruvian National Heart Institute. Methods: We studied 83 patients who underwent orthotopic heart transplantation at a single center between January 2010 and December 2019. The recipients’ profiles and survival were analyzed according to sex and age group, ensuring the information’s confidentiality. Results: The recipients’ mean age was 41.2 ± 17 years, 88% were adult, and 68.7% were male. The main indications for transplantation were idiopathic dilated cardiomyopathy. 85.5% of recipients were clinically categorized as INTERMACS Profile 1 to 3 before transplantation. There was a significant difference between sexes regarding the preoperative left ventricular ejection fraction and between age groups regarding the waiting time. The average ischemia time was 3.1 hours, operating time was 6.1 hours, cardiopulmonary bypass time was 3 hours, and aortic cross-clamp time was 1.7 hours. The principal early postoperative complications were hematological disorders and acute kidney failure. The principal late ones were kidney failure and severe anemia. The postoperative mortality was 15.9%, and the principal causes were infection and then acute rejection. The survival at one, five, and ten years was 87.5%, 79.8%, and 79.8%, respectively. The survival results were not influenced by sex or age group. Conclusion: Our patients’ postoperative complications, mortality, and survival rates coincided with those reported by the ISHLT registry.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 78%

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Heart transplantation at the Peruvian National Heart Institute: One-decade single-center experience

Pinto‐Salinas

Morón-Castro

Chavarri‐Velarde

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Results of heart retransplantation: subanalysis of the Spanish Heart Transplant Registry

Salterain-González

Juan-Áracil

Gómez‐Bueno

et al. 2022

Revista Española de Cardiología (English Edition)

View full text Add to dashboard Cite

COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital

López‐Vilella

Sánchez‐Lázaro

Trenado

et al. 2021

Transplantation Proceedings

View full text Add to dashboard Cite

Introduction : COVID 19 is a viral infectious disease caused by the SARS-CoV-2 virus that is affecting the entire world population. The objective of this study is to analyze the repercussion of the disease in a group of patients at risk such as heart transplants. Material and method : From February 2020 to February 2021, heart transplant patients diagnosed with COVID 19 were consecutively included. The total number of transplants in outpatient follow-up at that time was 381. 3 levels of infection were determined. A) Asymptomatic patients or with trivial symptoms without the need for hospital admission (6 patients). B) Patients admitted to the hospital for respiratory symptoms (12 patients). C) Patients with severe symptoms and need for admission to the Critical Care Unit (2 patients). At each risk level, medical performance was different. Thus, group A: Close control, no therapeutic modification. Group B: Reduction of calcineurin inhibitor (CNI) and substitution of mycophenolate mofetil (MMF) for everolimus (EVE). Group C: Reduction of ICN and withdrawal of MMF. Results : The prevalence of infection in the serie was 5.2%. Most of the patients admitted presented a pathological chest X-ray with fever, cough, dyspnea, or vomiting. The change in immunosuppression performed in group 2 patients was well tolerated and there was no graft rejection. Antiviral treatment was little used. However, boluses of steroids and some antibiotics were used frequently. The need for supplemental oxygen was 50% in group 2 and 100% in group 3. Conclusions : A significant number of transplant patients will be affected by COVID19 (5.3%). The management of the infection will depend on the severity of the infection and must be based on a balance between reduction and adjustment of immunosuppression, strict control of the cardiological situation, and treatment of the infection.

show abstract

Spanish Heart Transplant Registry. 31th Official Report of the Heart Failure Association of the Spanish Society of Cardiology

Cited by 6 publications

References 16 publications

Heart transplantation at the Peruvian National Heart Institute: One-decade single-center experience

Heart transplantation at the Peruvian National Heart Institute: One-decade single-center experience

Results of heart retransplantation: subanalysis of the Spanish Heart Transplant Registry

COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital

Contact Info

Product

Resources

About